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Abstract
Smoking is considered an important risk factor for bladder cancer (BC), yet molecular
characterization of BC in nonsmokers has not been extensively studied. Here, we
compare molecular differences between smokers and nonsmokers with BC. BC speci-
mens (676) proﬁled at a Clinical Laboratory Improvement Amendments-certiﬁed labo-
ratory from 2006 to 2014 were retrospectively evaluated for molecular differences
between smokers and nonsmokers. Protein expression was determined with immuno-
histochemistry. In situ hybridization was used for ERBB2 (HER2/neu) and EGFR evalua-
tion. Genes were evaluated using Sanger or next-generation sequencing. Thirty patients
were conﬁrmed lifetime nonsmokers (NS) and 39 were reformed or current smokers
(RCS). There was a trend for increased PIK3CA mutations in NS versus RCS (43% vs 11%,
p = 0.1760), whereas TP53 alterations were higher in RCS versus NS (63% vs 53%,
p = 0.6699). EGFR ampliﬁcation was observed more in NS versus RCS (22% vs 11%,
p = 0.5815), while HER2 was ampliﬁed only in RCS (23% vs 0%, p = 0.05). The molecular
differences between RCS and NS with BC suggest a different oncogenesis with poten-
tially different treatment options.
Patient summary: Bladder cancer patients with no history of smoking have different
molecular characteristics than those with smoking history. We found that smokers tend
to have higher incidence of HER2 ampliﬁcation, whereas nonsmokers seemed to have
higher PIK3CA mutation. This knowledge provides essential information, which can bear
relevance to treatment options.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
* Corresponding author. Penn State Hershey Cancer Institute, Division of Hematology and Oncology,
500 University Drive, Hershey, PA 17033, USA. Tel. +1-717-531-8678; Fax: +1-717-531-5076.
E-mail address: mjoshi@hmc.psu.edu (M. Joshi).Bladder cancer (BC), one of the most common malignancies
of the urinary tract [1], accounted for 16 000 cancer-related
deaths in 2015 [1]. Smoking is an important risk factor [2],
causing half of BC cases. Other risk factors include exposure
to aromatic amines, schistosomiasis, and genetic syn-
dromes (eg, germline Rb1 gene mutation, Cowden, LynchPlease cite this article in press as: Joshi M, et al. Molecular Characte
Urol Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.06.011
http://dx.doi.org/10.1016/j.euf.2016.06.011
2405-4569/# 2016 European Association of Urology. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/4.0/).syndromes, etc.) [3]. Cigarette smoke contains >60
carcinogens that can cause direct DNA damage leading
to unique mutational changes in smokers with lung cancer
[4]. Studies have shown that smokers with BC have worse
cancer specific mortality than nonsmokers [5] and that that
smoking exposure negatively affects disease recurrence,rization of Bladder Cancer in Smokers versus Nonsmokers. Eur
.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1 – Demographic details: the table shows the number of bladder cancer patients by age, smoking status, and specimen histology or
patient diagnosis
Patient Information
Cohort Lifetime NS Current smoker Reformed smoker
Total N 30 8 31
Median age (yr) 66 65 69
Specimens with staging 14/30 3/8 15/31
0is (Tis) 1 0 0
1 0 0 1
2 (T2) 4 0 1
3 (T3-4a) 5 0 4
4 (T4b or N+/M+) 4 3 7
Specimen Information
Histology (%) Lifetime NS Reformed and current smokers
Urothelial 24 (includes 2 with sarcomatous
differentiation)
33 (includes 1 micropapillary)
Nonurothelial 3 (2 adenocarcinoma, 1 neuroendocrine) 3 (1 adenocarcinoma, 2 squamous)
Not otherwise speciﬁed 3 3
Location/Site Lifetime NS Reformed and current smokers
Primary 24 (includes 8 TURBT, 4 partial or radical
cystectomy documented)
30 (includes 7 TURBT, 5 partial or radical cystectomy documented)
Metastatic 5 (4 lymphatic, 1 renal) 9 (4 lymphatic, 2 hepatic, 1 skin, 1 ileocecal, 1 pulmonary, 1 vaginal)
NS = nonsmoker bladder cancers; TURBT = transurethral resection of bladder tumor.
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patients [5]. The etiology behind such differences and
behind the development of BC in nonsmokers is poorly
understood. The Cancer Genome Atlas (TCGA) recently
published data detailing the molecular characterization of
BC [6], identifying potential therapeutic targets in 69% of
tumors, with roughly 42% aberrations identified in the
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit alpha (PIK3CA)/AKT/mechanistic target of rapamycin
pathway and 45% in the receptor tyrosine kinases/mitogen-
activated protein kinases pathway [6]. The initial published
dataset, comprised of 70% smokers/ex-smokers, identified no
significant differences between smokers and never-smokers,
although never-smokers had a slightly higher fraction of C>G
mutations than smokers [6]. Differences in protein expression
by immunohistochemistry (IHC) and gene amplification (in
situ hybridization [ISH]) have never been well studied based
on smoking status, although this is changing [7,8]. However,
with the advent of newer technologies, molecular characteri-
zation of BC based on smoking status demands further
exploration.
This study was Institutional Review Board exempt. Test
results of IHC, ISH, and hot-spot sequencing from BC samplesTable 2 – Amplification or rearrangement by fluorescence or chromog
cohort, p = 0.05)
Overall 
Biomarker Ampliﬁed Total Percent Ampliﬁed 
MET 2 221 0.9 0 
EGFR 47 217 21.7 2 
ERBB2 (HER2) 44 444 10.3 0 
TOP2A 3 56 5.4 0 
EGFR = epidermal growth factor receptor; HER2 = human epidermal growth f
NS = nonsmoker bladder cancers; TOP2A = topoisomerase II alpha; T = tumor; RC
Please cite this article in press as: Joshi M, et al. Molecular Characte
Urol Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.06.011(collected from 2006 to 2014) profiled at a commercial
Clinical Laboratory Improvement Amendments-certified
laboratory (Caris Life Sciences, Phoenix, AZ, USA) were
reviewed. Test methodologies were previously described [7].
Smoking status (nonsmokers [NS]; reformed or current
smokers [RCS]), age, and sex were available on a limited
number of patients. Fisher’s was utilized for statistical
analysis.
Of 696 BC cases profiled, smoking history was available
on 69 patients; 30 patients were lifetime NS; 39 patients
were classified RCS. Reformed smokers were defined as
patients who had stopped smoking for more than 5 yr at the
time of diagnosis. Patients with detailed past or current
smoking history (n = 9) averaged 57.8 pack yr (30–120 pack
yr). All others had a long history of smoking. Table 1
delineates patient cohorts and BC specimens.
In our survey, the NS cohort had a higher rate of PDGFRA
expression (30% vs 7.1%, p = 0.2721) and loss of PTEN
expression versus RCS (50% vs 38.5%, p = 0.4629). The RCS
cohort was twice as likely to be positive for HER2 expression
versus NS (12.8% vs 6.7%, p = 0.6905). EGFR amplification
was seen in 22% of NS versus 11% in RCS (p = 0.5815),
whereas HER2 was exclusively amplified in RCS (2.7% vs 0%,enic in situ hybridization (HER2 was exclusively amplified in thr RCS
NS RCS
Total Percent Ampliﬁed Total Percent
11 0.0 0 7 0.0
9 22.2 2 18 11.1
17 0.0 5 22 22.7
1 0.0 0 4 0.0
actor receptor 2; MET = MET proto-oncogene; M = metastases; N = node;
S = reformed or current smokers.
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Fig. 1 – Mutation frequency. Genes are shown from left to right by decreasing percent mutation. Genes with no alterations identified included ALK,
CSF1R, FGFR1, FLT3, GNA11, GNAQ, GNAS, JAK2, JAK3, MPL, NOTCH1, NPM1, PTPN11, and VHL. Genes seen in just one case included ABL, AKT1, ATM,
BRAF, CDH1, cKIT, cMET, HNF1A, KDR, MLH1, NRAS, PDGFRA, RET, SMAD4, and SMARCB1. Additionally, while no cases in the subgroup were tested for
BRCA1/2, the overall incidence in bladder cancer was 6.5% for BRCA1 and 13% for BRCA2. PIK3CA was found to be higher in nonsmokers (NS; 43%)
versus reformed or current smokers (RCS; 11%) but it did not reach statistical significance (p = 0.1760).
Hx = history.
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versus RCS (43% vs 11%, p = 0.1760; Fig. 1). All PIK3CA
mutations were in exon 1 (R88Q, x1) and exon 9 (E542K, x1;
E545K, x4), with none in exon 20. The PIK3CA mutation
(E545K) in the RCS cohort was in an individual with an 80-
pack yr history. Wnt pathway aberrations (ie, mutations in
APC or CTNNB1) occurred more frequently in RCS (APC N =
1/8; 12.5%; CTNNB1 N = 1/8; 12.5%) than NS (APC N = 1/12;
8.3%; CTNNB1 N = 0/12; 0%), p = 0.5530. IDH1 was found
exclusively in NS (8.3% vs 0%, p = 1.0). TP53 alterations (53%
NS vs 63% RCS, p = 0.6699) in RCS were R248W, R306X,
R196X, Y220C, and Y272L while the NS cohort contained no
A:T to G:C aberrations. No significant differences were
found in other genes. Please see Supplementary Table 1 and
2 for other biomarkers.
A subanalysis was performed on updated TCGA data on
412 BC specimens, comparing only biomarkers tested by
both TCGA and Caris. Differences between NS and RCS in the
412 TCGA cohort included TP53 (36% vs 52%, p = 0.007),
PIK3CA (12% vs 20%, p = 0.0593), ERBB2 (HER2) amplification
(3% vs 10%, p = 0.0217). Consistent with our findings, TP53
and HER2 trended higher in RCS versus NS. Of note, PIK3CA
seemed higher in the RCS than NS in TCGA, when compared
with our cohort, possibly due to selection bias.
Our retrospective analysis shows some differences in BC
biology in NS versus RCS. Smoking appears to be associated
with differences in molecular biology that could affect the
overall outcome in this subgroup. Presence of higher HER2
amplification and TP53 alterations may explain poor survival
in smokers. In both TCGA and our cohort, PIK3CA mutationPlease cite this article in press as: Joshi M, et al. Molecular Characte
Urol Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.06.011rates were not significantly different but the trends were
discordant, a finding worth verifying in a larger group of
patients to assess the correlation between PIK3CA mutation
in BC and smoking status. In our cohort, most PIK3CA
mutations were E545K (exon 9), which are recognized to play
a significant role in tumorigenesis [9]. IDH1 mutation was
only seen in the NS cohort. In the NS cohort, one (Y220C) of
the TP53-mutated specimens contained an A:T to G:C
transition, consistent with prior publications; no A:T to
G:C transitions were found in the RCS cohort [10]. Mutational
load, which has been implicated in smoking-associated
cancers, could not be assessed but a recent study found no
difference in the mutational burden in BC patients treated
with immunotherapy based on smoking status [11]. These
findings are certainly hypothesis generating; further studies
need to be done to understand the differences in molecular
biology of BC. Identification of differences in genomic
profiles between smoking cohorts could bear relevance
when selecting patients for clinical trials for targeted agents,
chemotherapy, or immunotherapy.
Our retrospective analysis highlights oncogenic differ-
ences based on smoking history. The study limitations
include a small sample size, heterogeneous cohort, lack of
biochemical verification of smoking status, selection bias,
and lack of uniformity of testing platforms for all patients.
Also, detection of CpG island methylation phenotype, the
latter of which was found to be significantly higher in
smokers per TCGA, were not performed by the reference
laboratory. To overcome these limitations, we plan to
evaluate the differences in molecular characterizationsrization of Bladder Cancer in Smokers versus Nonsmokers. Eur
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EUF-182; No. of Pages 4prospectively between BC patients with a thoroughly
documented smoking history and expanded gene coverage
to include emerging biomarkers in BC such as FGFR3 and
TSC1/2, to identify molecular drivers and elucidate different
therapeutic opportunities in the two populations.
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